Dive Brief:
- Fujifilm’s contract development and manufacturing organization has added 41 acres to its campus in Research Triangle Park, North Carolina, the corporation announced last week.
- Fujifilm Diosynth Biotechnologies’ acreage gain will allow it to expand for future production and development of biologics, according to the release.
- The now 119-acre campus currently includes more than 170,000 square feet of dedicated manufacturing space, as well as 151,000 square feet of process and analytical development.
Dive Insight:
Fujifilm has been heavily investing in its CDMO over the past year. In June, it announced plans to invest $1.6 billion to support batch production at its Hillerød, Denmark, site and to install proprietary manufacturing equipment at its Texas facility.
“Fujifilm is further expanding its bio CDMO business with the growth strategy of both capital investment and technological innovation to fulfill rapidly growing demand for high volume production of biopharmaceuticals,” Teiichi Goto, president, CEO and representative director of Fujifilm Corp. said in a statement on the investment.
Now, Fujifilm Diosynth Biotechnologies is set to add to its operations in Research Triangle Park. In addition to the land acquisition, the CDMO broke ground on a BioProcess Innovation Center last April to double its laboratory space in the region.
“With an established history in RTP, we’ve been able to build strong relationships with academia and the local, regional and state communities,” said COO of Fujifilm Diosynth Biotechnologies at Research Triangle Park Chris Vannais. “We look forward to continuing our growth ... so that we are well positioned to continue providing life-impacting theraputics.”
Fujifilm subsidiary Fujifilm Irvine Scientific is also set to build a manuacturing facility for cell culture solutions in the life sciences hub.
